Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Economic impact of diagnostic testing

9 evidence topics · 8 sources

Fibrosis staging required for coverage of resmetirom or semaglutide: liver biopsy, VCTE, MRE, or ELF test, national commercial prior authorization policy
Unit costs of the ELF test, transient elastography, imaging, and liver biopsy in hepatology workup, 2025 US dollars, model funded by a diagnostics manufacturer
Lifetime costs of FIB-4 and ELF screening strategies with resmetirom treatment of F2 to F3 fibrosis in high-risk US primary care patients, model funded by a diagnostics manufacturer

“We developed a decision-analytic model for MASLD natural history and treatment to compare 6 noninvasive test strategies using Fibrosis-4 (FIB-4) and/or enhanced liver fibrosis (ELF) tests at varying cutoffs. Patients identified with significant fibrosis were referred for hepatology staging (biopsy and/or imaging-based), and eligible individuals were considered for Resmetirom ($47,400/y; mean duration: 1.6–1.8 year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sequential screening with ELF (cutoff 9.80) following indeterminate FIB-4 (1.3–2.67) was the most cost-effective, yielding 8.610 QALYs and $96,990 in lifetime costs at a $100,000/QALY threshold. ELF-alone screening at a 9.00 cutoff maximized QALYs and individuals treated but increased unnecessary referrals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Resmetirom treatment costs were obtained from Centers for Medicare & Medicaid Services ($47,400/y at the time of analysis) and applied exclusively to individuals with F2-3 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Five-year direct costs of FIB-4 followed by ELF or VCTE screening of all US adults living with diabetes, 2026 to 2030, study funded by test and drug manufacturers

“This study aimed to estimate the direct healthcare costs of two MASLD and MASH screening strategies among all people living with diabetes in Brazil, Germany, Japan, the Kingdom of Saudi Arabia (KSA), Spain and the United States (US), from 2026 to 2030.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The Fibrosis‐4 (FIB‐4) index was used as the first line test, followed by the Enhanced Liver Fibrosis (ELF) test or vibration‐controlled transient elastography (VCTE) for confirmatory assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Over 5 years, the estimated costs of Strategy 1 ranged from R$0.7–1.3 billion for Brazil, €346–617 million for Germany, ¥80–172 billion for Japan, SAR 3.7–6.0 billion for the KSA, €591–949 million for Spain and $2.7–15.2 billion for the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Strategy 2 resulted in higher costs, ranging from R$1.2–2.0 billion for Brazil, €528–940 million for Germany, ¥121–262 billion for Japan, SAR 5.7–9.2 billion for the KSA, €0.9–1.4 billion for Spain and $4.1–23 billion for the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by Boehringer Ingelheim, Echosens and Novo Nordisk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Number of diagnostic tests and biopsy confirmation rate by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024